NewAmsterdam Total Stockholder Equity from 2010 to 2025
| NAMS Stock | 21.76 0.65 2.90% |
Total Stockholder Equity | First Reported 2010-12-31 | Previous Quarter 757.5 M | Current Value 795.4 M | Quarterly Volatility 281.2 M |
Check NewAmsterdam Pharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NewAmsterdam Pharma's main balance sheet or income statement drivers, such as Net Interest Income of 17.7 M, Interest Income of 17.7 M or Interest Expense of 0.0, as well as many indicators such as Price To Sales Ratio of 33.94, Dividend Yield of 0.0 or PTB Ratio of 3.36. NewAmsterdam financial statements analysis is a perfect complement when working with NewAmsterdam Pharma Valuation or Volatility modules.
NewAmsterdam | Total Stockholder Equity |
Latest NewAmsterdam Pharma's Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of NewAmsterdam Pharma over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. NewAmsterdam Pharma's Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NewAmsterdam Pharma's overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
NewAmsterdam Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 146,014,562 | |
| Coefficient Of Variation | 192.56 | |
| Mean Deviation | 217,716,344 | |
| Median | (3,577,000) | |
| Standard Deviation | 281,170,721 | |
| Sample Variance | 79057T | |
| Range | 799M | |
| R-Value | 0.74 | |
| Mean Square Error | 37886.4T | |
| R-Squared | 0.55 | |
| Significance | 0.001 | |
| Slope | 43,906,484 | |
| Total Sum of Squares | 1185854.6T |
NewAmsterdam Total Stockholder Equity History
About NewAmsterdam Pharma Financial Statements
NewAmsterdam Pharma shareholders use historical fundamental indicators, such as Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although NewAmsterdam Pharma investors may analyze each financial statement separately, they are all interrelated. The changes in NewAmsterdam Pharma's assets and liabilities, for example, are also reflected in the revenues and expenses on on NewAmsterdam Pharma's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 757.5 M | 795.4 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.